← Oncology Approval Tracker

FDA DECISION ·

Alunbrig

brigatinib · ARIAD Pharmaceuticals

Traditional approvalTraditional conversionNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic ALK-positive non-small cell lung cancer identified by an FDA-approved test, with the prior crizotinib treatment restriction removed.

LAMPGEN ANALYSIS

Why it matters

Converted the accelerated indication to regular approval and allowed treatment without prior crizotinib.

What research teams should watch

Confirm ALK status and build in early respiratory monitoring and dose escalation checks.

PRIMARY RECORDS

Sources